EMA grants first paediatric use marketing authorisation
September 9, 2011Sales and Marketing Buccolam, PUMA, Viropharma, paediatric trials, seizures
The first children’s medicine to hold a new paediatric use marketing authorisation (PUMA), making it available for children only, has …
European approval for prostate cancer drug Zytiga
September 8, 2011Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer
Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …
Everolimus approved to treat rare tumour disease
September 8, 2011Sales and Marketing Novartis, SEGA, Votubia, everolimus
Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …
New ABPI chief executive to focus on industry reputation
September 8, 2011Research and Development, Sales and Marketing ABPI, industry relations
The new chief executive of the ABPI used his first public speech to focus on the reputation of the pharma …
Sanofi banks on personalised medicine for growth
September 8, 2011Sales and Marketing Genzyme, Sanofi
Sanofi has nailed its colours to the mast of personalised medicine, banking on the purchase of US biotech company Genzyme, …
Algeta appoints first head of comms and investor relations
September 8, 2011Medical Communications, Research and Development appointment, medical communications, research and development
Norwegian biotech Algeta has appointed Dr Mike Booth to the newly-created role of senior VP of communications and corporate affairs. …
Dendreon drops GSK as Provenge manufacturing partner
September 8, 2011Manufacturing and Production Dendreon, GSK, Provenge, pharma manufacturing news
Dendreon has called a halt to its manufacturing and supply deal with GlaxoSmithKline for cancer vaccine Provenge, citing “delays and …
Forecasting future launch success
September 8, 2011Sales and Marketing Champix, Enbrel, forecast planning, forecasting
Pharmaceutical companies are moving into new and sometimes very different (often specialised) therapy areas, because of global market conditions and …
Clinical research news in brief
September 8, 2011Research and Development research and development news
This roundup includes using social media to recruit trial subjects, a strategic level service deal between BMS and Icon, plus …
Eisai shares risk with novel trial funding approach
September 7, 2011Research and Development Eisai, clinical trials, research and development news
Eisai has unveiled a novel risk-sharing approach to accelerate its late-stage research programme by accepting new sources of clinical trial …
Battle over health reform begins again
September 7, 2011Health and Social Care Bill, NHS, NHS reforms
The battle over the future of the NHS has began again as the Health and Social Care Bill yesterday returned …
NICE recommends Takeda’s cancer drug Mepact
September 7, 2011Sales and Marketing Mepact, NICE, Takeda
NICE has reversed its stance on Mepact and recommended the bone cancer drug after re-examining discounts and a new patient …
EMA should compare ‘like-for-like’ when assessing new drugs
September 7, 2011Research and Development EMA, clnical trials, research and development news
The European system of comparing drugs against placebo and not against a comparator is flawed, according to a new LSE …
Sanofi’s Multaq in the dock
September 7, 2011Sales and Marketing Multaq, Sanofi
The EMA will later this month decide whether Sanofi’s Multaq can remain on the market after reports emerged of serious …
AZ’s Nexium faces generic competition in the UK
September 6, 2011Nexium, Ranbaxy, generics
Generic specialist Ranbaxy has launched its version of AstraZeneca’s anti-ulcer blockbuster Nexium in the UK. It will be available in …
Lilly considering a stake in Turkish drugmaker
September 6, 2011Manufacturing and Production, Research and Development, Sales and Marketing MN Pharmaceuticals, Turkey, lilly, research and development news
Eli Lilly is reportedly eyeing up a partnership with Turkish drugmaker Mustafa Nevzat Ilac Sanayi (MN Pharmaceuticals) in order to …
New API production process ‘could transform pharma’
September 6, 2011Manufacturing and Production pharma manufacturing news, pharma production
UK researchers have started work on a new project to examine a new production method that they claim could “significantly …
Roche and Evotec to develop Alzheimer’s drug
September 6, 2011Alzheimer's disease, Evotec, Roche
Roche and Evotec are to collaborate on the development and commercialisation of Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease. …
Health reforms face renewed opposition
September 6, 2011Sales and Marketing NHS reforms
The government’s health reforms in England are coming under attack once again as the legislation returns to Parliament. After the …
CSL vaccine probe likely to rule out manufacturing errors
September 6, 2011Manufacturing and Production CSL Biotherapies, flu, pharma manufacturing news, vaccines
CSL Biotherapies has said that manufacturing errors were likely not to blame for febrile seizures in children who received its …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
